Literature DB >> 25164809

PDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade.

Zhibo Liu1, Xinxin Chen1, Ying Wang2, Haiyong Peng1, Yanan Wang1, Yanling Jing1, Hongbing Zhang3.   

Abstract

Mechanistic target of rapamycin (mTOR) integrates multiple extracellular and intracellular signals to regulate cell growth and survival. Hyperactivation of mTOR has been observed in various cancers. Regulation of mTOR activity is thus of importance in physiological processes and tumor development. Here, we present pyruvate dehydrogenase kinase 4 (PDK4) as a novel regulator of mTORC1 signaling. mTORC1 activity was augmented with PDK4 overexpression and reduced by PDK4 suppression in various cell lines. Furthermore, PDK4 bound to cAMP-response element-binding protein (CREB) and prevented its degradation. The enhanced CREB consequently transactivated the expression of Ras homolog enriched in brain (RHEB), a direct key activator of mTORC1, independent of AMP-activated protein kinase or tuberous sclerosis complex protein 2. PDK4 potentiated the mTORC1 effectors hypoxia-inducible factor 1α and pyruvate kinase isozymes M2 and promoted aerobic glycolysis (Warburg effect). Knockdown of PDK4 suppressed the tumor development of cancer cells with activated mTORC1. The abundance of PDK4 dictated the responsiveness of cells to the mTOR inhibitor, rapamycin. Combinatory suppression of mTOR and PDK4 exerted synergistic inhibition on cancer cell proliferation. Therefore, PDK4 promotes tumorigenesis through activation of the CREB-RHEB-mTORC1 signaling cascade.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Cellular Regulation; DNA-Protein Interaction; Mechanistic Target of Rapamycin (mTOR); Pyruvate Dehydrogenase Kinase 4; Ras Homolog Enriched in Brain; Signaling; Tumorigenesis; Warburg Effect; cAMP-response Element-binding Protein (CREB)

Mesh:

Substances:

Year:  2014        PMID: 25164809      PMCID: PMC4207987          DOI: 10.1074/jbc.M114.584821

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  Transcriptional regulation by the phosphorylation-dependent factor CREB.

Authors:  B Mayr; M Montminy
Journal:  Nat Rev Mol Cell Biol       Date:  2001-08       Impact factor: 94.444

2.  Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Authors:  Christine C Hudson; Mei Liu; Gary G Chiang; Diane M Otterness; Dawn C Loomis; Fiona Kaper; Amato J Giaccia; Robert T Abraham
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

3.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.

Authors:  Ken Inoki; Yong Li; Tianquan Zhu; Jun Wu; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

4.  Akt regulates growth by directly phosphorylating Tsc2.

Authors:  Christopher J Potter; Laura G Pedraza; Tian Xu
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

5.  Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin.

Authors:  Andrew R Tee; Rana Anjum; John Blenis
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

6.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.

Authors:  Hongbing Zhang; Gregor Cicchetti; Hiroaki Onda; Henry B Koon; Kirsten Asrican; Natalia Bajraszewski; Francisca Vazquez; Christopher L Carpenter; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

7.  Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia.

Authors:  Katrina M Comerford; Martin O Leonard; Jorn Karhausen; Robyn Carey; Sean P Colgan; Cormac T Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

8.  mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.

Authors:  H Peng; J Liu; Q Sun; R Chen; Y Wang; J Duan; C Li; B Li; Y Jing; X Chen; Q Mao; K-F Xu; C L Walker; J Li; J Wang; H Zhang
Journal:  Oncogene       Date:  2012-10-29       Impact factor: 9.867

9.  Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.

Authors:  Attila Garami; Fried J T Zwartkruis; Takahiro Nobukuni; Manel Joaquin; Marta Roccio; Hugo Stocker; Sara C Kozma; Ernst Hafen; Johannes L Bos; George Thomas
Journal:  Mol Cell       Date:  2003-06       Impact factor: 17.970

10.  Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

Authors:  Andrew R Tee; Diane C Fingar; Brendan D Manning; David J Kwiatkowski; Lewis C Cantley; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

View more
  32 in total

1.  PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia.

Authors:  Fabrizio Pin; Leah J Novinger; Joshua R Huot; Robert A Harris; Marion E Couch; Thomas M O'Connell; Andrea Bonetto
Journal:  FASEB J       Date:  2019-03-20       Impact factor: 5.191

2.  PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1.

Authors:  Shuo Yu; Yang Li; Hui Ren; Hong Zhou; Qian Ning; Xue Chen; Tinghua Hu; Lan Yang
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-21       Impact factor: 3.333

3.  Regulation of Pyruvate Dehydrogenase Kinase 4 in the Heart through Degradation by the Lon Protease in Response to Mitochondrial Substrate Availability.

Authors:  Clair Crewe; Christopher Schafer; Irene Lee; Michael Kinter; Luke I Szweda
Journal:  J Biol Chem       Date:  2016-11-17       Impact factor: 5.157

4.  A network medicine approach to build a comprehensive atlas for the prognosis of human cancer.

Authors:  Fan Zhang; Chunyan Ren; Kwun Kit Lau; Zihan Zheng; Geming Lu; Zhengzi Yi; Yongzhong Zhao; Fei Su; Shaojun Zhang; Bin Zhang; Eric A Sobie; Weijia Zhang; Martin J Walsh
Journal:  Brief Bioinform       Date:  2016-08-24       Impact factor: 11.622

5.  Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.

Authors:  Yang Zhang; Yi Zhang; Liying Geng; Haowei Yi; Wei Huo; Geoffrey Talmon; Yeong C Kim; San Ming Wang; Jing Wang
Journal:  J Biol Chem       Date:  2016-06-21       Impact factor: 5.157

6.  Loss of PDK4 switches the hepatic NF-κB/TNF pathway from pro-survival to pro-apoptosis.

Authors:  Jianguo Wu; Yulan Zhao; Young-Ki Park; Ji-Young Lee; Ling Gao; Jiajun Zhao; Li Wang
Journal:  Hepatology       Date:  2018-05-20       Impact factor: 17.425

7.  Arsenic silences hepatic PDK4 expression through activation of histone H3K9 methylatransferase G9a.

Authors:  Xi Zhang; Jianguo Wu; Jonathan Choiniere; Zhihong Yang; Yi Huang; Jason Bennett; Li Wang
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-20       Impact factor: 4.219

Review 8.  Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers.

Authors:  Nam Ho Jeoung
Journal:  Diabetes Metab J       Date:  2015-06       Impact factor: 5.376

9.  Different Blood Cell-Derived Transcriptome Signatures in Cows Exposed to Vaccination Pre- or Postpartum.

Authors:  Rosemarie Weikard; Wiebke Demasius; Frieder Hadlich; Christa Kühn
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

10.  Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells.

Authors:  William Walter; Jennifer Thomalla; Josh Bruhn; Dedra H Fagan; Cheryl Zehowski; Douglas Yee; Andrew Skildum
Journal:  Springerplus       Date:  2015-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.